Keywords
Neurology
Neuromuscular junction diseases
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the characteristics of Myasthenia Gravis (MG). Bibliographic review: MG is an antibody-mediated autoimmune disease that affects the postsynaptic membrane at the neuromuscular junction, being produced by different antibodies against synaptic membrane proteins. This is generally, in more than 85% of cases, caused by a type of antibody against the skeletal muscle acetylcholine receptor (AChR-ab). The disease is rare; the estimated annual incidence is 1 to 2 cases per 100,000, and its worldwide prevalence is 150 to 250 cases per million individuals. Final considerations: MG is a neuromuscular junction disorder whose main clinical feature is fluctuating weakness that worsens with exercise and improves with rest. Its diagnosis is clinical, laboratory with serologies for antibodies associated with the disease and from tests such as electromyography. MG therapy involves symptom control with Pyridostigmine and modulation with steroidal and non-steroidal immunosuppressive therapies. Currently, there is still the option of using intravenous immunoglobulin and plasma exchange.
References
ALHAIDAR MK, et al. Current Treatment of Myasthenia Gravis. J Clin Med, 2022; 11(6): 1597.
BOURQUE PR e BREINER A. Myasthenia gravis. CMAJ, 2018; 190(38): E1141.
BRIL V, et al. A Review of Disease Mechanisms and Current and Emerging Treatment Options for Generalized Myasthenia Gravis. Prim Care Companion CNS Disord, 2022; 24(3): AR21018WC2C.
BUBUIOC AM, et al. The epidemiology of myasthenia gravis. J Med Life, 2021; 14(1): 7-16.
CHENG W, et al. A systematic review of myasthenia gravis complicated with myocarditis. Brain Behav, 2021; 11(8): e2242.
DEYMEER F. Myasthenia gravis: MuSK MG, late-onset MG and ocular MG. Acta Myol, 2020; 39(4): 345-352.
DUAN W, et al. Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis. Front Neurol, 2022; 13: 1018509.
ESTEPHAN EP, et al. Myasthenia gravis in clinical practice. ArqNeuropsiquiatr, 2022; 80(5): 257-265.
FARRUGIA ME e GOODFELLOW JA. A Practical Approach to Managing Patients With Myasthenia Gravis-Opinions and a Review of the Literature. Front Neurol, 2020; 11: 604.
LASCANO AM e LALIVE PH. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev, 2021; 20(1): 102712.
LAZARIDIS K e TZARTOS SJ. Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management. Front Neurol, 2020; 11: 596981.
LEHNERER S, et al. Burden of disease in myasthenia gravis: taking the patient's perspective. J Neurol, 2022; 269(6): 3050-3063.
LI HF, et al. Editorial: Phenotypes of myasthenia gravis. Front Neurol, 2022; 13: 1025183.
MENON D e BRIL V. Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. Drugs, 2022; 82(8): 865-887.
MORREN JA e LI Y. Myasthenia gravis: Frequently asked questions. Cleve Clin J Med, 2023; 90(2): 103-113.
NARAYANASWAMI P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology, 2021; 96(3): 114-122.
NELKE C, et al. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J Neuroinflammation, 2022; 19(1): 89.
PAYET CA, et al. Myasthenia Gravis: An Acquired Interferonopathy? Cells, 2022; 11(7): 1218.
PUNGA AR, et al. Editorial: Advances in Autoimmune Myasthenia Gravis. Front Immunol, 2020; 11: 1688.
ROUSSEFF RT. Diagnosis of Myasthenia Gravis. J Clin Med, 2021; 10(8): 1736.
SALARI N, et al. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med, 2021; 19(1): 516.
SCHNEIDER-GOLD C e GILHUS NE. Advances and challenges in the treatment of myasthenia gravis. Ther Adv Neurol Disord, 2021; 14: 17562864211065406.
SHEIKH S, et al. Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update. J Clin Med, 2021; 10(7): 1537.
SONG Z, et al. Different Monoclonal Antibodies in Myasthenia Gravis: A Bayesian Network Meta-Analysis. Front Pharmacol, 2022; 12: 790834.
WOLFE GI, et al. IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis. J Neurol Sci, 2021; 430: 118074.
WU Y, et al. Immunoregulatory Cells in Myasthenia Gravis. Front Neurol, 2020; 11: 593431.
YI JS, et al. B cells in the pathophysiology of myasthenia gravis. Muscle Nerve, 2018; 57(2): 172-184.
ZHOU Q, et al. To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis. Front Immunol, 2021; 12: 733418.